Status:
COMPLETED
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Lead Sponsor:
Fred Hutchinson Cancer Center
Conditions:
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing na...
Detailed Description
OBJECTIVES: I. To determine whether the incidence of nausea and vomiting related to administration of autologous hematopoetic stem cells cryopreserved in DMSO can be reduced by the use of a single do...
Eligibility Criteria
Inclusion
- Inclusion
- Autologous PBSC transplant patient
- English-speaking
- Planned cryopreserved PBSC infusion at the SCCA outpatient clinic
- Exclusion
- History of prior autologous transplant
- Non-English-speaking
- Planned cryopreserved PBSC infusion at the UWMC inpatient unit
- Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion
- Allergy or adverse reaction to ondansetron
Exclusion
Key Trial Info
Start Date :
August 8 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 10 2009
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00795769
Start Date
August 8 2008
End Date
June 10 2009
Last Update
May 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109